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Abstract
Background: Insufficient persistence and effector function of chimeric antigen receptor (CAR)-redirected T cells
have been challenging issues for adoptive T cell therapy. Generating potent CAR T cells is of increasing importance
in the field. Studies have demonstrated the importance of the Akt pathway in the regulation of T cell differentiation
and memory formation. We now investigate whether inhibition of Akt signaling during ex vivo expansion of CAR T
cells can promote the generation of CAR T cells with enhanced antitumor activity following adoptive therapy in a
murine leukemia xenograft model.
Methods: Various T cell subsets including CD8+ T cells, bulk T cells, central memory T cells and naïve/memory T cells
were isolated from PBMC of healthy donors, activated with CD3/CD28 beads, and transduced with a lentiviral vector
encoding a second-generation CD19CAR containing a CD28 co-stimulatory domain. The transduced CD19CAR T cells
were expanded in the presence of IL-2 (50U/mL) and Akt inhibitor (Akti) (1 μM) that were supplemented every other
day. Proliferative/expansion potential, phenotypical characteristics and functionality of the propagated CD19CAR T cells
were analyzed in vitro and in vivo after 17-21 day ex vivo expansion. Anti-tumor activity was evaluated after adoptive
transfer of the CD19CAR T cells into CD19+ tumor-bearing immunodeficient mice. Tumor signals were monitored with
biophotonic imaging, and survival rates were analyzed by the end of the experiments.
Results: We found that Akt inhibition did not compromise CD19CAR T cell proliferation and expansion in vitro,
independent of the T cell subsets, as comparable CD19CAR T cell expansion was observed after culturing in the
presence or absence of Akt inhibitor. Functionally, Akt inhibition did not dampen cell-mediated effector function,
while Th1 cytokine production increased. With respect to phenotype, Akti-treated CD19CAR T cells expressed
higher levels of CD62L and CD28 as compared to untreated CD19CAR T cells. Once adoptively transferred into
CD19+ tumor-bearing mice, Akti treated CD19CAR T cells exhibited more antitumor activity than did untreated
CD19CAR T cells.
Conclusions: Inhibition of Akt signaling during ex vivo priming and expansion gives rise to CD19CAR T cell populations
that display comparatively higher antitumor activity.
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Background
Adoptive transfer of in vitro-expanded chimeric antigen
receptor (CAR) T cells genetically modified to express
tumor-targeted antigen receptors can result in dramatic
regressions of B cell leukemia [1, 2]. However, insufficient
persistence and effector function of CAR-redirected T
cells in vivo has been a challenge for adoptive T cell ther-
apy [3–6]. Manufacturing CAR T cells is a process that in-
volves activation and ex vivo culture with IL-2 to facilitate
CAR gene transfer and to achieve a therapeutic number of
T cells. This process is also associated with decreased anti-
tumor activity due to terminal differentiation [7].
Studies indicate that transfer of potent CAR T cells
with central memory traits can enhance antitumor im-
munity and the curative potential of adoptive therapy for
cancer [8–10]. Recent studies have highlighted the im-
portance of the Akt and Wnt pathways in the regulation
of CD8+ T cell differentiation and memory formation
[11–14]. Upon engagement of cell surface receptors such
as the T cell receptor, co-stimulatory molecules, and
cytokine receptors, the PI3K-Akt pathway is activated,
resulting in downstream responses via phosphorylating a
range of intracellular proteins. Akt activation is required
for T cell activation [11]. However, studies have shown
that the sustained activity of Akt progressively drives T
cells toward terminal differentiation and diminished
anti-tumor activity [11]. Crompton and van der Waart
et al. have shown that reduction of Akt activation during
T cell ex vivo expansion resulted in potent tumor-
infiltrating lymphocytes (TIL) and T cells specific for
minor histocompatibility antigens (MiHAs) on tumors
[15, 16]. We therefore hypothesized that manipulation of
the magnitude of Akt activation may prevent terminal
differentiation of CAR T cells as they are expanded to a
therapeutic dose. To evaluate this hypothesis, we trans-
duced and expanded CD19CAR T cells in the presence
of an Akt inhibitor. We show that Akt inhibition during
ex vivo expansion did not inhibit CD19CAR T cell pro-
liferation and effector function but gave rise to less dif-
ferentiated CAR T cells with high expression of CD62L
and CD28 [7]. Additionally, the CAR T cells expanded in
the presence of the Akt inhibitor appeared to have en-
hanced antitumor activity in vivo. Taken together, these
findings suggest the use of pharmacologic approaches
during the ex vivo expansion of CAR T cells could




Unless stated otherwise, all cell lines were maintained in
RPMI 1640 (Irvine Scientific) supplemented with 2 mM L-
glutamine, 25 mM HEPES, and 10% heat-inactivated FCS
(Hyclone). PBMCs were transformed with Epstein-Barr
virus to generate lymphoblastoid cell lines (LCLs) as
previously described [17]. To generate OKT3-expressing
LCLs (LCL OKT3), allogeneic LCLs were re-suspended in
nucleofection solution using the Amaxa Nucleofector
kit. OKT3-2A-Hygromycin_pEK plasmid was added to
5 mg/107 cells, the cells were electroporated using
Amaxa Nucleofector I, and the resulting cells were
grown in RPMI-1640 with 10% FCS containing 0.4 mg/mL
hygromycin. To generate firefly luciferase (ffluc) + GFP+
CD19+ lymphoid leukemic cells, SupB15 cells obtained
from ATCC were transduced with a lentiviral vector en-
coding eGFP-ffluc. Initial transduction efficiency was 50%;
therefore, the GFP cells were sorted by FACS for >98%
purity (fflucGFPSupB15s).
Antibodies and flow cytometry
Human T cells were analyzed by flow cytometry after
staining with fluorochrome-conjugated monoclonal anti-
bodies (mAbs) to CD8 (SKI), CD62L (Dreg-56), CD45RO
(UCHL1), CD45RA (L48), CD28 (CD28.2), CD3 (SK7),
IFN-γ (XMG1.2), CD107a (H4A3), KLRG1 (2 F1/KLRG1),
CD57 (HNK-1), Tim3 (F38-2E2), PD1 (EH12.1), LAG3
(FAB2319C), and phosphorylated Akt (pAkt, pS473)(M89-
61) (BD Biosciences). Data acquisition was performed on
a MACSQuant (Miltenyi Biotec) and analyzed using
FCS Express, Version 3 software (De Novo Software).
Telomere length analysis was performed using the
flow-FISH technique with Telomere PNA Kit/FITC ob-
tained from Dako (Dako Denmark A/S, Denmark). Bio-
tinylated Erbitux (cetuximab) and streptavidin-PE were
used to identify T cells that expressed truncated human
EGFR (EGFRt). Anti-CD4 microbeads were purchased
from Stemcell Technologies, and anti-CD14, anti-CD45RA,
and anti-CD25 microbeads were purchased from Miltenyi
Biotec. Proliferation capacity was determined by labeling
the cells with carboxyfluorescein succinimidyl ester (CFSE)
(Invitrogen).
Generation of CD19 CAR T cells
For isolation of CD8+ T cells, CD4+ T cells in PBMCs
were labeled with anti-CD4 microbeads and depleted
with the EasySep system (Stemcell Technologies). The
freshly isolated CD4 negative cells were activated with
CD3/CD28 Dynabeads (Invitrogen) and transduced the
next day with a lentivirus encoding CD19R (EQ):CD28:ζ/
EGFRt at an MOI of 3 and expanded in the presence of
50U/mL rhIL-2 (CellGenix) and 1 μM Akt inhibitor VIII
(Akti-1/2) (Merck Millipore). Cultures were then supple-
mented with 50 U/mL rhIL-2 (CellGenix) and Akt inhibi-
tor every 48 h for 17–21 days before in vitro analysis and
adoptive transfer. Transduced CD19CAR T cells without
Akt inhibitor treatment were used as control, as were
non-transduced mock cells from the same donor. In some
experiments, bulk T cells, purified CD62L + CD45RO+
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central memory (TCM) and CD62L+ naïve/memory T cells
were engineered with CD19CAR using the selection
platform that we have developed [18]. Briefly, for TCM
isolation, fresh PBMC were incubated with anti-CD14,
anti-CD45RA, and anti-CD25 microbeads, and the
resulting labeled cells were then immediately depleted
using the CliniMACS™ depletion mode to remove
CD14+ monocytes, CD25 + Treg T cells and CD45RA+
naïve T cells. The resulting unlabeled negative fraction
cells were then labeled with biotinylated-anti-CD62L
(DREG56) mAb and anti-biotin microbeads. The
CD62L + CD45RO + TCM were purified with positive
selection. Similarly, fresh PBMC were incubated with
anti-CD14 and anti-CD25 microbeads, and the result-
ing labeled cells were then immediately depleted using
the CliniMACS™ to remove CD14+ monocytes and
CD25 + Treg T cells. The resulting unlabeled negative
fraction cells were then labeled with biotinylated-anti-
CD62L mAb and anti-biotin microbeads. The CD62L+
naïve/memory T cells were purified with positive selection.
DNA constructs
The lentivirus CAR construct was modified from the
previously described CD19-specific scFvFc:ζ chimeric
immunoreceptor [19] to create a second-generation vec-
tor. The CD19CAR containing a CD28z costimulatory
domain carries mutations at two sites (L235E; N297Q)
within the CH2 region on the IgG4-Fc spacers to ensure
enhanced potency and persistence after adoptive transfer
[20]. The lentiviral vector also expresses a truncated hu-
man epidermal growth factor receptor (huEGFRt), which
includes a cetuximab (Erbitux) binding domain but ex-
cludes the EGF-ligand binding and cytoplasmic signaling
domains. A T2A ribosome skip sequence links the codon-
optimized CD19R:CD28:ζ sequence to the huEGFRt se-
quence, resulting in coordinate expression of both
CD19R:CD28:ζ and EGFRt from a single transcript [21].
The CD19CARCD28EGFRt DNA sequence (optimized
by GeneArt) was then cloned into a self-inactivating
(SIN) lentiviral vector, pHIV7 (gift from Jiing-Kuan
Yee, Beckman Research Institute of City of Hope,
Duarte, CA) (Additional file 1: Figure S1).
CFSE proliferation
Ex vivo expanded CD8 + CD19CAR T cells with and
without Akt inhibitor treatment were labeled with
0.5 mM CFSE and co-cultured with CD19+ LCLs as
stimulator cells for 5 days in the presence of 50U/L
rhIL-2. CFSE dilution of CD3 and CAR double positive
populations was determined using multicolor flow cy-
tometry. In some experiments, CD19CAR T cells derived
from PBMC and TCM were used for proliferation assays.
Degranulation and cytokine production assays
Ex vivo expanded CD8 + CD19CAR T cells (105) with
and without Akt inhibitor treatment were co-cultured
with LCLs (105) in medium containing Golgi plug (BD)
and antibody against CD107a for six hours at 37 °C.
Acute myeloid leukemia KG1a cells were used as a nega-
tive stimulator and LCL OKT3 as positive stimulator.
Degranulation was determined using multicolor flow cy-
tometry. Ex vivo expanded CD8 + CD19CAR T cells with
and without Akt inhibitor treatment (105) were co-
cultured in 96-well tissue culture plates with 105 of the
indicated stimulator cells. Supernatants were harvested
18 h after stimulation, and cytokines were measured by a
cytometric bead array using the Bio-Plex Human Cytokine
Panel (Bio-Rad Laboratories) (in triplicates) according to
the manufacturer’s instructions.
Xenograft model
To establish a leukemic model, acute lymphoid leukemic
SupB15 cells were engineered with GFP firefly luciferase
(GFPffluc+), and 0.5 × 106 purified GFP+ cells were inoc-
ulated into six- to ten-week old NOD/Scid IL-2RγCnull
(NSG) mice intravenously (i.v) on day -5. After confirm-
ation of the tumor engraftment, 1–2 × 106 expanded
CD19CAR T cells were adoptively transferred into
tumor-bearing mice intravenously. Tumor signals were
monitored by Biophotonic tumor imaging.
Statistical analysis
Analyses were performed using Prism (GraphPad Software
Inc.). The Mann-Whitney t- and Log-rank (Mantel-Cox)
tests were used to ascertain the statistical significance
of the in vivo data (tumor signals and survival). The
Wilcoxon matched-pairs signed rank test (2-tailed) was
used for the analysis of in vitro data except the cytokine
data assumed to have a normal distribution in tripli-
cates were analyzed with paired t test. P < 0.05 was con-
sidered statistically significant.
Results
Akt inhibition does not compromise CD19CAR T cell
proliferation and expansion
To investigate the effects of Akt inhibition on CAR T
cell expansion and function, we first sought to confirm
that the Akt inhibitor (Akti) in culture can reduce phos-
phorylation of Akt, especially serine residue phosphoryl-
ation. Akti VIII, which selectively inhibits Akt1/Akt2
activity, has been shown to be able to induce memory T
cell formation at a concentration of 1 μM [16]. We
therefore transduced purified CD8+ T cells and ex-
panded CD8 + CD19CAR T cells in the presence of
1 μM Akti. After two to three weeks of ex vivo expan-
sion, intracellular pAkt in the CD8 + CD19CAR T cells
were analyzed with flow cytometry. We consistently
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found that 1 μM Akti resulted in a trend toward modest
reduction (73.1 ± 2.5 to 64.0 ± 1.5%) of phosphorylation
of Akt on serine 473 in CD19CAR T cells across four
different donors, but left total Akt signaling unaltered
(N = 4, P = 0.1) (Fig. 1a and b). We then investigated
whether this level of reduction of Akt affects CAR T cell
proliferation and expansion. Interestingly, we did not
observe an effect of Akt inhibition on proliferation based
on the CFSE dilution of CD8+ CD19CAR T cells (Fig. 1c),
nor of bulk PBMC and TCM derived CD19CAR T cells
(79.1 ± 13.6% of untreated vs. 77.6 ± 14.9% of Akti-treated
CD19CAR T cells) (Fig. 1d). Total cell growth was not
compromised by inhibition of Akt signaling during 17 days
of ex vivo expansion, which is the maximum days of T cell
expansion used in our current clinical trials, indicating the
intact proliferation and expansion capacity of Akti-treated
CD19CAR T cells (Fig. 1e). These data were consistent
with CD8+ T cells from multiple donors (Fig. 1f). For
most adoptive T cell therapies, CAR T cell products are
derived from a mixture of T cell populations containing
both CD4+ and CD8+ T cells. We further analyzed the
impact of the Akt inhibitor on the CD19CAR T cells con-
taining both CD4+ and CD8+ subsets. Again, proliferation
and expansion were not inhibited in this composition of
CD19CAR T cells (Fig. 1g). Considering that the activation
threshold of various T cell subsets differs [22, 23], a study
of the impact of Akti on the various T cell subsets was
performed. Purified TCM and naïve/memory T cells were
activated, transduced and expanded in the presence of
1 μM Akti. Consistently, we observed no negative effects
of Akti on ex vivo expansion of all the T cell subsets tested
(Fig. 1g).
Akt inhibition generates CD19CAR T cell populations with
memory-like characteristics
CD3/CD28 bead stimulation and activation have been
used for engineering CAR T cells to improve transduction
efficiency and expansion to a therapeutic dose. However,
the levels of stimulation are super-physiological, and over-
stimulation possibly induces terminal differentiation and
functional impairment of CAR T cells [24], which could
be one reason for poor antitumor response observed in
some patients. Our hypothesis was that Akti would de-
crease the magnitude of activation and therefore pre-
serve memory-like T cells with improved potential for
persistence and antitumor activity after adoptive trans-
fer. Expanded T cells were analyzed for memory T cell
characteristics. After 17 days of ex vivo culture of CD8 +
CD19CAR T cells, expression of CD62L was 18.2% ± 7.1
in the Akti-untreated culture and 33.9% ± 11.3 in the
Akti-treated counterparts (N = 4, P = 0.1). CD62L + CAR+
double positive cells were 34.9% ± 9.7 and 58.0% ± 9.7
(N = 4, P = 0.2) in the Akti-untreated culture and in the
Akti-treated counterparts, respectively (Fig. 2a and b).
Consistently, when gated CAR+ cells were analyzed,
Akti-treated CD8 + CD19CAR T cells co-express higher
levels of CD62L and CD28 as compared to the un-
treated CD19CAR T cells (50.3% ± 3.7 vs.10.3% ± 4.8)
(N = 4, P = 0.1) (Fig. 2c and d), suggesting that Akti-
expanded CD8 + CD19CAR T cells appear less differen-
tiated and possess a memory phenotype. To further
understand the levels of senescence and exhaustion of
the CD8 + CD19CAR T cells, we analyzed expression of
KLRG1, CD57, Tim3, PD1 and LAG3, which are known
to be the hallmarks of exhaustion. Our data support that
Akti did not increase the senescence of CD8 + CD19CAR
Tcells (Fig. 2e). We also measured and compared the rela-
tive telomere lengths. In line with the findings that Akti
had no effects on proliferative capacity and senescence of
the CD8 + CD19CAR, Akti-treated, purified CD8 +
CD19CAR T cells derived from three donors maintained
relatively equal telomere length (Fig. 2f ) as compared
to untreated CD8 + CD19CAR T cells (N = 3, P = 0.3).
Although purified TCM and naïve/memory T cells
originally express high levels of CD62L (80%), after
activation/lentiviral transduction and ex vivo expan-
sion, CD62L expression decreased to 40–50%. Con-
sistently, Akti addition preferentially retained CD62L
expression on the cultured cells (Fig. 3a) to 50–80%.
The same results were observed when unselected
bulk T cells were tested. These studies demonstrate
that manipulation of levels of Akt activation could
prevent differentiation derived from CD3/CD28
activation/expansion and promote enhanced central
memory T cell subsets. Consistent with engineered
CD19CAR T cells from purified CD8+ T cells, CD28 +
CD62L + CAR+ T cells derived from bulk PBMC, TCM
and naïve/memory T cells are significantly higher in the
Akti treated conditions as compared to untreated counter-
parts (N = 6, P = 0.03) (Fig. 3b). However, exhaustive
features remain the same, indicating that Akti prevents
CAR T cell differentiation and does not induce exhaustion
of CAR T cells (Fig. 3c).
Akt inhibition does not dampen cell-mediated cytotoxicity
but increases cytokine production
Akt activation appears to be essential for the develop-
ment of effector function in activated CD8+ T cells
[25] and is required for efficient adoptive therapy. To
assess this functionality, we analyzed Akti-treated
CD8 + CD19CAR T-cells for degranulation ability
upon co-culture with different targets. We found
equivalent levels of CD107a + cells in CD19CAR and
Akti-treated CD19CAR T cells upon CD19+ tumor
stimulation (24.9 ± 15 vs. 27.8 ± 13.4%, respectively)
(Fig. 4a and b). Maximum degranulation remained the
same as indicated by the degranulation ability after stimu-
lation with LCL OKT3, which engages the entire T cell
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receptor (TCR), suggesting that the tumor-specific and in-
trinsic capacity of effector function was not affected by
Akt inhibition. Cytokine production, another benchmark
of effector function, was analyzed. Cytokines that were re-
leased into the supernatant after stimulator and responder















































































































































Fig. 1 Akt inhibition does not compromise CD19CAR T cell proliferation and expansion. CD8+ T cells in PBMC from healthy donors were isolated
by CD4+ T cell depletion following anti-CD4 microbeads labeling and magnetic selection with the EasySep system. The freshly isolated CD4 negative cells
were activated with CD3/CD28 Dynabeads and transduced the next day with CD19R (EQ):CD28:ζ/EGFRt lentivirus at an MOI of 3, then expanded. The
cultures were supplemented with 50 U/mL rhIL-2 and 1 μM Akt inhibitor every 48 h for 17–21 days before in vitro analysis. Transduced CD19CAR T cells
without Akt inhibitor treatment were used as control. a Expanded CD8 + CD19CAR T cells were harvested and stained intracellularly with antibodies
against phosphorylated Akt pS473 and total Akt. Fluorescence minus one (FMO) are depicted in red histograms. Histograms are of gated CD19CAR+ T
cells. b Percentages of phosphorylated Akt positive cells from four different donors are presented. c Expanded CD8 + CD19 CAR T cells were labeled with
0.5 mM CFSE and then co-cultured with CD19+ LCLs as stimulators for 5 days in the presence of 50U/L rhIL-2. CFSE dilution of gated CD3+ and CAR+
double positive populations was determined using multicolor flow cytometry. Percentages of CFSE negative cells over non-stimulated cells are presented.
d Percentages of CFSE negative CAR T cells derived from different T cell subsets are depicted. e CD8+ T cells were transduced with lentivirus encoding
CD19CAR vector and expanded in a medium containing 50U/L rhIL2, in the presence and absence of 1 μM Akt inhibitor. Viable cell numbers were
determined by Guava ViaCount at the indicated time points. f Data on day 17 from four different donors are presented. g Bulk T cells, purified TCM and
purified naïve/memory T cells were transduced with lentivirus encoding second generation CD19CAR vector and expanded in a medium containing
50U/L rhIL2, in the presence and absence of 1 μM Akt inhibitor. Viable cell numbers were determined by Guava ViaCount at the indicated time points.
Mock T cells from the same donor were used as controls
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Significantly higher levels of Th1 cytokines IFNγ (P < 0.05)
and GM-CSF (P < 0.05) were produced by CD8 +
CD19CAR T cells treated with Akti (Fig. 4c) upon CD19
antigen (LCL) stimulation, indicating a population with
greater effector function. However, Th2 cytokines such as
IL-10, IL-4, and IL-6 that hamper the induction of effect-
ive of T cell response were not significantly increased
upon CD19 antigen stimulation (Fig. 4d).
Akti-expanded CD19CAR T-cells appeared to exhibit
greater anti-tumor efficacy and expansion in vivo
The principal aim of the study was to determine
whether Akti promotes the generation of CAR T cells
with enhanced antitumor activity. Building on the
memory-like phenotypic traits and improved cytokine
production, we anticipated that Akti-expanded CD8 +
CD19CAR T cells would possess enhanced anti-tumor
Fig. 2 Akt inhibition generates CD8 + CD19CAR T cell populations with memory-like characteristics. CD8 + CD19CAR T cells that had been cultured in
the presence and absence of 1 μM Akti were stained with biotinylated Erbitux (cetuximab), followed by streptavidin-PE for CAR detection and antibodies
against CD8, CD62L, CD28, KLRG1, CD57, Tim3, PD1, and LAG3. a Percentages of CD62L+ and CAR + CD62L+ double positive cells are depicted on the
basis of the gating of isotype-stained cells. b Percentages of CD62L+ and CAR + CD62L+ double positive cells from four different donors are presented.
c Expression and percentages of CD62L and CD28 after gating on CAR+ cells are presented. d Percentages of CD62L + CD28 + CAR+ cells after gating
on CAR+ cells. Data from four different donors are presented. e Mean percentages of immunoreactive cells + SEM from 4 different donors are presented.
f In vitro expanded CD8 + CD19CAR+ T cells were collected. Relative telomere length of T cells was determined with Telomere PNA detection kit and
normalized against 1301 cell line as control. Means + SEMs of duplicates from three different donors are depicted. RTL = (mean FL1 sample cells with
probe-mean FL1 sample cells without probe) × DNA index of control cells ×100/(mean FL1 control cells with probe-mean FL1 control cells without
probe) × DNA index of sample cells
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activity once transferred into B cell leukemia tumor-
bearing mice. To test the antitumor activity, we deliv-
ered a suboptimal (2 × 106) dose of CD8 + CD19CAR
T-cells intravenously into mice following systemic in-
oculation of human CD19+ leukemic cells. Tumor
burden in the mice was monitored on a weekly
basis, and Kaplan-Meier survival analysis was per-
formed. Consistent with the in vitro observation,
untreated CD8 + CD19CAR T cells induced transient
tumor regression, but tumors re-progressed rapidly.
In contrast, mice treated with an equal number of
Akti-treated CD8 + CD19CAR exhibited significantly
higher antitumor activity (p = 0.02) with significantly
prolonged survival (p = 0.008) (Fig. 5). One mouse
had no evidence of tumor 100 days from inoculation.
We also tested the anti-tumor activity of bulk CD19
CAR-T cells containing CD4 T cells and CD8 T cells
that were expanded in the presence of Akti and
compared them with non-treated cells having the same
proportion of CD4, CD8, and CAR subsets. We again
observed what appeared to be more tumor regression
when mice were treated with Akti-treated CD19CAR T
cells than untreated counterpart (Fig. 6a, b, and c).
Furthermore, 40 days post CAR T cell transfer, higher levels
of human Tcells and CAR Tcells were detected in the mice
that received Akti-treated CD19CAR T cells than that in
Fig. 3 Akt inhibition promotes the generation of memory CD19CAR T cells from different T cell subsets. a Bulk T cells, purified TCM, and purified
naïve/memory T cells were transduced with lentivirus encoding second generation CD19CAR vector and expanded in a medium containing 50U/L
rhIL2, in the presence and absence of 1 μM Akt inhibitor for 17–21 days. Resultant CD19CAR T cells were stained with biotinylated Erbitux (cetuximab),
followed by streptavidin-PE for CAR detection and antibodies against CD62L. Percentages of CAR + CD62L+ cells are depicted on the basis of the
gating of isotype-stained cells. b Percentages of CD62L + CD28+ T cells after gating on CAR + CD8+ from six lines derived from two different donors
are presented. c Mean percentages of immunoreactive cells + SEMs from six lines of two different donors are presented
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the mice that received non-Akti-treated counterparts, al-
though the results are not statistically significant (Fig. 6d).
Percentages of CAR T cells in the harvested blood were
similar to the input cells (~30%) (Fig. 6e), suggesting
that Akti-treated CD19CAR T cells were proportion-
ately expanded in vivo following adoptive transfer. To
demonstrate Akti has similar impacts on different T cell
subsets, propagated CD19CAR T cells derived from
purified TCM and naïve/memory T cells in the presence
and absence of Akti were tested for their antitumor ac-
tivity in vivo. Consistently, Akti-treated CD19CAR TCM
(Fig. 7a and b) and naïve/memory T cells (Fig. 7c and d)
exhibited greater antitumor activity as compared with
their untreated counterparts even though the CD4+
CAR T cells are dominant in the TCM populations. To
rule out the xeno-reactivity of infused Akti-treated
CD19CAR T cells, mouse body weight, an indicator of
GVHD, was measured. We observed no evidence of
GVHD such as loss of body weight (Additional file 2:
Figure S2) and hair loss, on day 28, when the highest
active antitumor activity occurred.
Discussion
Effective T cell therapy against cancer is dependent on
the formation of long-lived memory T cells with the ability
to self-renew and differentiate into potent effector cells.
These goals have been approached by various means, in-
cluding using defined central memory T cells as a starting
population for gene modification, optimizing CAR design,
and supplementing with cytokine cocktails during ex vivo
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Fig. 4 Akt inhibition does not dampen cell-mediated cytotoxicity but increases cytokine production of CD8 + CD19CAR T cells. After 21 days of in
vitro expansion, a CD8 + CD19CAR T-cells with and without Akt inhibitor treatment were co-cultured with LCLs at a 1:1 ratio in medium containing
Golgi plug and CD107a for six hours at 37 °C. KG1a cells were used as negative stimulator and LCL OKT3 as positive stimulator. Degranulation was
determined using multicolor flow cytometry. Percentages of CAR + CD107a + T cells are presented. b Accumulated data from three different donors
are presented. c CD8 + CD19CAR T cells with and without Akt inhibitor treatment were co-cultured with LCLs at a 1:1 ratio in medium for eighteen
hours at 37 °C. Supernatants were harvested and cytokines were measured by a cytometric bead array. Means + SEMs of triplicates are depicted. KG1a
cells were used as a negative stimulator and LCLOKT3 as positive stimulator
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expansion [8, 18, 26, 27]. All of these strategies are
feasible, but validation before translating to a clinical
platform is costly and time-consuming. There are sev-
eral pharmacologic candidates capable of driving T cells
toward the memory phenotype, such as those activating
the Wnt/β-catenin pathway [14] and inhibiting m-TOR
mediated protein translation [28]. However, the con-
centration required for significant inhibition of T cell
differentiation might also lead to immunosuppressive
and anti-proliferative activity [29, 30]. Our data support
that addition of Akti at 1 μM during ex vivo expansion
did not interfere with CD8 + CD19 CAR T cell prolifer-
ation and expansion. The same results were also ob-
served in different T cell subsets such as bulk T cell,
TCM, and naïve/memory-derived CD19CAR T cells, in-
dicating that this is a general feature of the Akti on T
Fig. 5 Akti-treated CD8 + CD19CAR T cells exhibit increased anti-tumor efficacy in vivo. 0.5 × 106 acute lymphoid leukemic SupB15 cells engineered
with GFP firefly luciferase (GFPffluc+) were inoculated into NSG mice intravenously (i.v) on day -5. After confirmation of tumor engraftment, 2 × 106
expanded CD8 + CD19CAR+ T cells were adoptively transferred into tumor-bearing mice intravenously. Non-transduced mock cells from the same
donor were used as controls. a Tumor signals were monitored by biophotonic tumor imaging and b the bioluminescence signal was measured as
total photon flux normalized for exposure time and surface area and expressed in units of photons (p) per second per cm2 per steradian (sr).
c Kaplan-Meier survival curve. N = 4 mice per group
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cell proliferation and expansion and therefore can be
used for clinical manufacturing of therapeutic doses of
CAR T cell products without the restriction of starting
T cell populations. Our data indicated that Akti at 1 μM
resulted in modest reduction (12%) of phosphorylated Akt
in the CAR T cells. A ~5-fold increase in concentration is
anticipated to further reduce phosphorylated Akti at Ser
473 [31]. However, careful titration of Akti during CAR T
cell generation is necessary to maximize potency without
suppressing T cell expansion and function. The optimal
concentration of Akti may additionally vary among the
various T cell subsets as starting population. Efficient CAR
T cell therapy relies on potent effector function and in
vivo persistence following adoptive transfer. Our studies
Fig. 6 Akti-treated CD4 + CD19CAR+ and CD8 + CD19CAR T cells exhibit increased anti-tumor efficacy and persistence in vivo. PBMC from healthy
donors were activated with CD3/CD28 Dynabeads and transduced the next day with CD19R (EQ):CD28:ζ/EGFRt lentivirus at an MOI of 3. The cultures
were supplemented with 50 U/mL rhIL-2 and Akt inhibitor every 48 h for 21 days. Transduced CD19CAR T cells without Akt inhibitor treatment were used
as control. Non-transduced mock T cells were used as another type of control. a Percentages of CD8 and CAR positive cells in the input population are
presented. b Acute lymphoid leukemic 0.5 × 106 SupB15 cells engineered with GFPffluc were inoculated into NSG mice (N = 3 mice per group)
intravenously (i.v) on day -5. After confirmation of the tumor engraftment, 1 × 106 expanded CD19CAR+ T cells were adoptively transferred
into tumor-bearing mice intravenously. Tumor signals were monitored by Biophotonic tumor imaging and c the bioluminescence signal was
measured as total photon flux normalized for exposure time and surface area and expressed in units of photons (p) per second per cm2 per
steradian (sr). d Forty days post adoptive transfer, mice were euthanized, and blood were analyzed after staining with antibodies against human CD45,
CD8 and cetuximab for CAR detection. Mean percentages of human CD45 positive and GFP (tumor) negative cells from three mice are presented. e
CD8+ and CAR T cells gated on CD45 positive human T cells are depicted
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demonstrated that manipulation of levels of Akt activation
enhanced the antigen-specific effector function of
CD19CAR T cells as indicated by elevated Th1 cytokines
such as IFNγ and GM-CSF while preventing differenti-
ation. Studies have shown that T cells with memory char-
acteristics positively correlate with in vivo persistence and
antitumor activity post adoptive transfer [32]. Despite no
statistically significant differences as a result of variation
among donors and a limited number of donors, our
studies consistently demonstrated that Akti-treated
CD19CAR T cells exhibited higher expression levels of
CD62L and CD28 without expression of exhaustion
phenotypes such as KLRG1, which are the traits re-
quired for efficient anti-tumor activity following adop-
tive transfer [33]. In further support, there did not
appear to be a difference in telomere length between
cultures with or without Akti. Upon transfer into CD19
tumor-bearing mice, Akti-treated CD8 + CD19CAR T
cells efficiently inhibited tumor growth and induced
long-term survival as a result of improved antitumor
activity and/or expansion. The role of the Akt signaling
pathway in CD4+ cells is more complicated and poorly
understood than in CD8+ cells because of the interplay
of regulatory versus conventional CD4+ T cells that
contain different CD4+ T cell subsets. However, more
tumor reduction in the mice treated with an Akti-
inhibited mixture of CD4 + CD19CAR and CD8 + CD19
CAR T cells indicates the minor impact of Akti-treated
Tregs on the overall therapeutic effects. This validates
the use of Akti when both CD4+ and CD8+ T cells are
included in the starting population for CAR T cell en-
gineering and manufacturing. We also found that Akti-
treated CAR T cells did not induce alloreactivity, an im-
portant safety consideration. Built on the pre-clinical
studies [8–10, 34] demonstrating that TCM and naive/
memory T cells possess characteristics that correlate
with improved anti-tumor activity, current clinical trials
have developed a clinical platform for purification,
transduction, and expansion of CD19CAR TCM for
adoptive immunotherapy, with the goal of long-term
CAR T cell disease surveillance [35]. Our current studies
demonstrate that Akti does not inhibit TCM and naïve/
Fig. 7 Akti-treated CD19CAR TCM + and CD19CAR naïve/memory T cells exhibit greater anti-tumor efficacy in vivo. TCM and naïve/memory T cells
from healthy donors were isolated and activated with CD3/CD28 Dynabeads and transduced the next day with CD19R (EQ):CD28:ζ/EGFRt lentivirus at
an MOI of 3. The cultures were supplemented with 50 U/mL rhIL-2 and Akt inhibitor every 48 h for 21 days. Transduced CD19CAR T cells without Akt
inhibitor treatment were used as control. Non-transduced mock T cells were used as another type of control. Acute lymphoid leukemic 0.5 × 106
SupB15 cells engineered with GFPffluc were inoculated into NSG mice (N = 5 mice per group) intravenously (i.v) on day -5. After confirmation of the
tumor engraftment, 1 × 106 expanded CD19CAR+ T cells were adoptively transferred into tumor-bearing mice intravenously. Tumor signals were
monitored by Biophotonic tumor imaging and the bioluminescence signal was measured as total photon flux normalized for exposure time and
surface area and expressed in units of photons (p) per second per cm2 per steradian (sr). a Percentages of CD8 and CAR positive cells in the input
CD19CAR TCM population are presented. b Tumor signals at different time points are presented. c Percentages of CD8 and CAR positive cells in the
input CD19CAR naïve/memory population are presented. d Tumor signals at different time points are presented
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memory-derived CD19CAR T cell expansion but pro-
motes the generation of memory CD19CAR T cells with
greater antitumor activity and supports the use of Akti for
further improved CAR T cell therapy in these advanced
platforms. The underlying mechanisms may be related to
changes in metabolic and transcriptional signatures char-
acteristic of long-lived memory T cells that are repro-
grammed by Akt inhibition [16, 25, 36]. Meanwhile, our
data support that Akt inhibition has no impact on replica-
tive senescence based on the lack of changes in relative
telomere length and exhaustive features.
Conclusion
Our data suggest that inhibition of Akt signaling during
ex vivo priming, expansion, and culturing gives rise to a
CD19CAR T cell population that possesses increased an-
titumor activity. These findings suggest that therapeutic
modulation of Akt might be a strategy to augment anti-
tumor immunity for adoptive CAR T cell therapy, which
could easily be transitioned into the clinic with the avail-
ability of a pharmaceutical grade Akt inhibitor.
Additional files
Additional file 1: Figure S1. Schematic of the CD19CAR-T2A-EGFRt.
The CD19R:zeta DNA sequence (optimized by GeneArt) contains the
chimeric antigen receptor (CAR) sequence consisting of the VH and VL
gene segments (scFv) of the CD19-specific FMC63 monoclonal antibody
(mAb); IgG4 hinge containing the 2 point mutations, L235E and N297Q
in the CH2 portion (CD19R(EQ)); the CD28 costimulatory domain; signaling
domains CD3 zeta; and the self-cleaving T2A and the truncated EGFR
(EGFRt) sequences. (EPS 1663 kb)
Additional file 2: Figure S2. CD19CAR T cells expanded in the presence
of Akti did not induce allo-reactivity in xenograft model. T cell subsets were
isolated and activated with CD3/CD28 Dynabeads and transduced the next
day with CD19R (EQ):CD28:zeta/EGFRt lentivirus at an MOI of 3. The cultures
were supplemented with 50 U/mL rhIL-2 and Akt inhibitor every 48 h for
21 days. Acute lymphoid leukemic 0.5 × 106 SupB15 cells engineered with
GFPffluc were inoculated into NSG mice intravenously (i.v) on day -5. After
confirmation of the tumor engraftment, 1 × 106 expanded CD19CAR+ T
cells were adoptively transferred into tumor-bearing mice intravenously.
Transduced CD19CAR T cells without Akt inhibitor treatment were used
as control. Non-transduced mock T cells were used as another type of
control. Body weight was measured on day 28 post T cell infusion,
when the most active antitumor activity occurred in CD19CAR Akti
treated mice. Means ± SEMs are presented. Number of mice in each
group is presented on the top of the bar. (EPS 1490 kb)
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